

# **Buprenorphine Waiver Application & Management**

“Medication-First” Model



# Objectives

- Review of medication-assisted treatment
- Statewide efforts to integrate “medication first” model
- Columbia efforts to pilot ED-initiated programming
- Review DATA 2000 waiver application process
- Provide local and national training resources



# Medication-Assisted Treatment

- What Is It?
  - Medication-assisted treatment (MAT) incorporates the use of FDA-approved medications and behavioral therapy in the treatment of Opioid Use Disorder (OUD).
- Which Agencies Endorse MAT?
  - Substance Abuse and Mental Health Services Administration
  - American Medical Association
  - National Institute on Drug Abuse

# “Medication First” Model

- Address withdrawal symptoms
- Reduce cravings
- Enable the patient to focus and engage in counseling and social support groups
- Increase treatment retention
- Supported by the Missouri Department of Mental Health
- Key component of the Opioid STR Grant



# Obstacles to MAT

- Access
  - Need for more waiver-trained prescribers to use buprenorphine for treatment
  - Community services for support and treatment
- Funding
- Stigma
  - A shift from abstinence-models (12-step)
  - Lack of awareness of evidence-based treatment



# Medication First Model — EPICC Project


- Patient overdoses and arrives in the ED.
- Buprenorphine induction occurs in the ED.
- A Recovery Coach is contacted and meets with the patient in the ED.
- The ED physician provides the patient with a bridge prescription of 3-5 days of buprenorphine.
- The Recovery Coach assists the patient with a timely referral to outpatient MAT, behavioral therapy, and recovery support services, including housing.



# EPICC Project Results



ED Referral Volume by Month  $n=643$



Source: Behavioral Health Network (2018) EPICC Project, six-month report, July-December 2017

# EPICC Demographic Profile



## Active Opioid Overdose Clients (12/2016 – 12/2017; n=643)

<b>Gender</b>	Male 57.7%	Female 42.3%			
<b>Race</b>	Caucasian 46%	African American 44%	Refused 10%		
<b>Age</b>	18-25 15%	26-35 42%	36-45 26%	46-64 15%	<b>&gt;65 2%</b>
<b>Currently Enrolled in any Substance Use Tx?</b>			Yes 2.1%	No 97.9%	
<b>Client Reported as Homeless*</b>			Yes 30%	No 70%	
<b>Client Reported Active Insurance</b>			Yes 33%	No 67%	
<b>Narcan Provided through Recovery Coach</b>			Yes 88%	No 12%	
<b>Overdose Education Provided through Recovery Coach**</b>			Yes 95%	No 5%	

**Source: Data obtained from Efforts to Outcomes (ETO) database**

# Why is Waiver Training Required?

- **Harrison Narcotics Tax Act of 1914:** Physicians were allowed to prescribe narcotics to patients in the course of treatment except for the treatment of addiction.
- **Drug Addiction Treatment Act of 2000:** Waiver-trained physicians were allowed to prescribe buprenorphine as part of MAT.
- **Comprehensive Addiction and Recovery Act of 2016:** Buprenorphine waiver training was expanded to include nurse practitioners and physician assistants.



# The Drug Addiction Treatment Act (DATA 2000)

- ❖ Expands the clinical context of medical treatments for opioid dependency
- ❖ Allows physicians to dispense or prescribe specifically approved Schedule III, IV, and V narcotic medications – that have a lower risk for abuse, like buprenorphine
- ❖ Reduces the regulatory burden on physicians who choose to practice opioid dependency treatment

Source: <https://www.samhsa.gov/programs-campaigns/medication-assisted-treatment/legislation-regulations-guidelines#DATA-2000>

# Comprehensive Addiction and Recovery Act (CARA 2016)


One of CARA's important provisions expands access to substance use treatment services and overdose reversal medications:

- ❖ Providing a full spectrum of services from prevention to medical treatments of opioid use disorder and recovery support.
- ❖ Extends the privilege of prescribing buprenorphine in office-based settings to qualifying nurse practitioners (NPs) and physician assistants (PAs) until Oct. 1, 2021.



# FDA Approved Medications for Treatment of Opioid Use Disorder

Medication	Action	Dispensing
Methadone	Full agonist--Full agonists (like heroin, morphine, hydrocodone, and oxycodone) bind to opioid receptors and create a response proportional to the dose.	Opioid Treatment Program (OTP)
Buprenorphine	Partial agonist—Partial agonists bind to opioid receptors, cause a limited reaction, and prevent the euphoric effect.	Any prescriber with waiver
Naltrexone	Antagonist—Antagonists bind to opioid receptors and block the receptors from being activated.	Any prescriber



Source: <https://store.samhsa.gov/shin/content/SMA14-4852/SMA14-4852.pdf>

# Naltrexone

- Antagonist used in conjunction with counseling and social support
- Blocks opioid receptors thereby negating misuse/diversion risk
- The pill form of naltrexone (ReVia, Depade) can be taken once per day.
- The injectable extended-release form of the drug (Vivitrol) is administered once a month
- May be prescribed by any healthcare provider who is licensed to prescribe without special training
- Challenge: the patient must be opioid free for 7-10 days prior to administration of naltrexone

Source: <https://www.samhsa.gov/medication-assisted-treatment/treatment/naltrexone>



# Waiver Process and Required Training MD and DO

In order to prescribe or dispense buprenorphine – physicians must qualify for a waiver – MD's and DO's are required to obtain 8 hours of initial training

- ❖ Completing eight hours of the DATA-waiver course for opioid use disorder
- ❖ Apply for waiver

<https://www.samhsa.gov/medication-assisted-treatment/buprenorphine-waiver-management/qualify-for-physician-waiver>



# Waiver Process and Required Training NP and PA

In order to prescribe or dispense buprenorphine – nurse practitioners and physician assistants must qualify for a waiver – NP's and PA' are required to obtain no fewer than 24 hours of initial training

- ❖ Completing eight hours of the DATA-waiver course for opioid use disorder
- ❖ Completing sixteen hours of additional clinical coursework
- ❖ Apply for waiver

<https://www.samhsa.gov/programs-campaigns/medication-assisted-treatment/training-materials-resources/qualify-np-pa-waivers>



# Buprenorphine Waiver Application

- ❖ Notify SAMHSA Center for Substance Abuse Treatment (CSAT) of your intent to practice this form of medical treatment for opioid use disorder
- ❖ The notification of intent must be submitted to CSAT before the initial dispensing or prescribing of opioid treatment.

<https://www.samhsa.gov/medication-assisted-treatment/buprenorphine-waiver-management/apply-for-physician-waiver>



# Buprenorphine Waiver Notification

The screenshot shows a web browser window with the URL [buprenorphine.samhsa.gov/forms/select-practitioner-type.php](http://buprenorphine.samhsa.gov/forms/select-practitioner-type.php). The page title is "Buprenorphine Waiver Notification" and it includes a "View Practitioner Profile" link. The content is organized into two main sections:

### System Use Notification

- You are accessing a U.S. Government information system, which includes (1) this computer, (2) this computer network, (3) all computers connected to this network, and (4) all devices and storage media attached to this network or to a computer on this network. This information system is provided for U.S. Government-authorized use only.
- Unauthorized or improper use of this system is prohibited and may result in disciplinary action, as well as civil and criminal penalties.
- Personal use of social media on this system may result in disciplinary action unless otherwise authorized.
- By using this information system, you understand and consent to the following:
  - You have no reasonable expectation of privacy regarding any communication or data transiting or stored on this information system. At any time, and for any lawful Government purpose, the government may monitor, intercept, and search and seize any communication or data transiting or stored on this information system.
  - The government may record and audit your information system usage, including usage of personal email systems to conduct HHS businesses.
  - Any communication or data transiting or stored on this information system may be disclosed or used for any lawful Government purpose.

### Before you begin

Before starting this application, please make sure you have

- Your DEA Number
- Your State Medical License Number
- Your Training Certificate Information

After submitting application waiver, submit your training certificate to [csatbupinfo@dsgonline.com](mailto:csatbupinfo@dsgonline.com)

Do you work for the US military, Veterans Administration, or Indian Health Service?

Yes  No

For more information, contact the SAMHSA Center for Substance Abuse Treatment's (CSAT's) Buprenorphine Information Center at 866-BUP-CSAT (866-287-2728) or send an email to [infobuprenorphine@samhsa.hhs.gov](mailto:infobuprenorphine@samhsa.hhs.gov).

The browser's taskbar at the bottom shows the time as 2:41 PM on 3/14/2018.

# DEA Identification and Registration Numbers

- ❖ DEA assigns the qualified physician a special identification number. DEA regulations require this identification number and the physician's regular DEA registration number on all buprenorphine prescriptions for opioid dependence treatment.
- ❖ Under DATA 2000, individual physicians can treat up to 30 patients in opioid dependence treatment at a time for the first year.
- ❖ One year after the initial notification is submitted, the physician may submit a second notification of the need and intent to treat up to 100 patients.

<https://www.samhsa.gov/medication-assisted-treatment/buprenorphine-waiver-management/qualify-for-physician-waiver>



## Final Rule (2016) Expanding Access To Medication-Assisted Treatment

- ❖ This new regulation allows practitioners to treat up to 275 patients
- ❖ There are two pathways through which practitioners can become eligible to increase their patient limit to 275:
  - 1) Having additional credentialing in addiction medicine or addiction psychiatry from a specialty medical board and/or professional society
  - 2) Working in a qualified practice setting, which provides comprehensive treatment associated with buprenorphine maintenance
  - 3) Practitioners who are approved to treat up to 100 patients are eligible to raise their patient limit up to 275 to ensure continuity of care for patients

# Buprenorphine Training for Practitioners

The following SAMHSA-supported continuing medical education (CME) courses can help physicians qualify to prescribe buprenorphine in an office setting:

- ❖ Buprenorphine [Waiver Training](#) at the **American Academy of Addiction Psychiatry**
- ❖ The **American Society of Addiction Medicine** offers the [ASAM Buprenorphine Course](#)
- ❖ The **Providers Clinical Support System** the [PCSS-MAT course](#)



# Missouri Buprenorphine Waiver Training

## Training requirements

- ❖ Physicians – eight hours
- ❖ Nurse practitioners and physician assistants – 24 hours

Missouri Coalition for Community Behavioral Healthcare provides the waiver training

## Resources:

- ❖ <https://www.mocoalition.org/medication-assisted-treatment>  
(schedule)
- ❖ <https://katiehorst.wufoo.com/forms/z1fglcxq1u8h0fg/>  
(reimbursement)



# Upcoming Missouri Waiver Trainings

All three upcoming trainings are “Half and Half”, meaning half of the training is provided in-person, and half is provided online. Registration and venue information will be released soon.

- ❖ **Saturday, May 12, 2018 – Half and Half Training - Columbia, Missouri:** [Register](https://katiehorst.wufoo.com/forms/z1tvvupa07j2szu/) online now <https://katiehorst.wufoo.com/forms/z1tvvupa07j2szu/>
- ❖ **Saturday, June 2, 2018 – Half and Half Training – St. Louis, Missouri:** [Register](https://katiehorst.wufoo.com/forms/znhsvbd1udf6xj/) online now <https://katiehorst.wufoo.com/forms/znhsvbd1udf6xj/>
- ❖ **Saturday, September 29, 2018 – Half and Half Training – Kansas City, Missouri:** [Register](https://katiehorst.wufoo.com/forms/z1h3ax300k39net/) online now: <https://katiehorst.wufoo.com/forms/z1h3ax300k39net/>



# Contact Information

Shawn Billings

Opioid Project Manager

[sbillings@mhanet.com](mailto:sbillings@mhanet.com)

(573) 893-3700, ext. 1409

